February 5, 2019

Zhiqiang Qin, M.D., Ph.D.

Associate Professor

Department of Pathology, UAMS College of Medicine

Research Interest Statement

My research interest focuses on using Kaposi’s sarcoma-related herpesvirus (KSHV) as a model pathogen to study the mechanisms of viral oncogenesis and identify the key viral and/or host factors that contribute to the pathogenesis of this oncogenic virus. My group has established KSHV+ primary effusion lymphoma (PEL) and Kaposi’s sarcoma (KS) xenograft models, which can be widely used in identifying the oncogenic role of host/viral factors in PEL or KS progression in vivo and test novel therapeutic agents against these virus-associated malignancies. My group is interested in understanding how the interaction of KSHV and other co-infected pathogens such as periodontal bacteria, several opportunistic pathogenic bacteria, as well as HPV, can contribute to oncogenic virus pathogenesis. We also do some research on common cancers usually seen in AIDS patients, especially lung cancer.


Winthrop P. Rockefeller Cancer Institute

Seeds of Science Pilot Grant

Role of EIF4G1 in Non-Small Cell Lung Cancer Pathogenesis

02/01/2019 – 01/31/2020

Principal Investigator



National Institutes of Health/National Cancer Institute


Peridontal bacteria enhance oral KSHV pathogenesis and Kaposi’s sarcoma development in HIV+ patients

05/01/2018 – 04/30/2023

Principal Investigator


*cancer-related annual direct costs

Dr. Qin’s UAMS Collaborators

Steven Post, Ph.D. (Pathology)

Craig Forrest, Ph.D. (Microbiology and Immunology)

Hong-Yu Li, Ph.D. (Pharmaceutical Sciences)

Dr. Qin’s External Collaborators

Pinghui Feng, Ph.D. (University of Southern California)

Shoujiang Gao, Ph.D. (University of Pittsburgh)

Erik Flemington, Ph.D.  (Tulane University)

Luis Del Valle, M.D. (Louisiana State University Health Science Center)

Maryam Foroozesh, Ph.D. (Louisiana Xavier University)

Wei Jiang, M.D. (Medical University of South Carolina)

Opportunities for Collaboration

I welcome any kind of collaboration with basic and physician scientists, infectious disease clinicians, hematology oncologists, clinical pathologists, and bioinformaticians for oncogenic viruses and other cancer research. We are especially interested to develop novel anti-herpesvirus or anti-cancer agents through the collaboration.

You Might Not Know That

I would like to join some teams to play soccer and/or basketball on weekends since we just moved to Little Rock. I also like to collect DVDs and CDs to watch and listen after a busy day at work, and I found Goodwill is a wonderful place to find interesting ones.

Cancer-Related Publications

Dai L, Del Valle L, Miley W, Whitby D, Ochoa AC, Flemington EK, Qin Z. Transactivation of human endogenous retrovirus K (HERV-K) by KSHV promotes Kaposi’s Sarcoma development. Oncogene. 2018;37(33):4534-4545.

Dai L, Smith CD, Foroozesh M, Miele L, Qin Z. The sphingosine kinase 2 inhibitor ABC294640 displays anti-non-small cell lung cancer activities in vitro and in vivo. Int J Cancer. 2018;142(10):2153-2162.

Dai L, Lin Z, Qiao J, Zabaleta J, Flemington EK, Qin Z. Ribonucleotide reductase represents a novel therapeutic target in primary effusion lymphoma. Oncogene. 2017;36(35):5068-5074.

Bonsignore L, Passelli K, Pelzer C, Perroud M, Konrad A, Thurau M, Stürzl M, Dai L, Trillo-Tinoco J, Del Valle L, Qin Z, Thome M. A role for MALT1 activity in Kaposi’s sarcoma-associated herpes virus latency and growth of primary effusion lymphoma. Leukemia, 2017; 31(3):614-624.

Dai L., Trillo-Tinoco J., Cao Y., Bonstaff K., Doyle L., Valle LD., Whitby D., Parsons C., Reiss K., Zabaleta J., Qin, Z. Targeting HGF/c-MET induces cell cycle arrest, DNA damage and apoptosis for primary effusion lymphoma. Blood, 2015;126(26):2821-31.